Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 141Breast Neoplasms 10Neoplasm Metastasis 8Neoplasms 5Bulbo-Spinal Atrophy, X-Linked 5Triple Negative Breast Neoplasms 4Salivary Gland Neoplasms 3Prostate Adenocarcinoma 2Osteoporosis 2Lower Urinary Tract Symptoms 2Hirsutism 2Thrombocytosis 1Stage I Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Sexual Dysfunction, Physiological 1Recurrence 1Primary Myelofibrosis 1Primary Dysautonomias 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × bicalutamide × Clear all
NCT06222593 2026-04-01

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

State University of New York at Buffalo

Phase 1/2 Recruiting
28 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡